Harnessing the power of the immune system

OUR FOCUS

Brooklyn ImmunoTherapeutics is focused on exploring the role that the human immune system can have in treating patients with cancer and immunologic diseases, both as a single agent and in combination with other therapies.

Our most advanced program is a Phase 2b clinical trial studying the safety and efficacy of IRX-2, a human cell-derived (hd) IL-2 therapeutic in patients with head and neck cancer. In a Phase 2a clinical trial in head and neck cancer, IRX-2 was well-tolerated and demonstrated an overall survival benefit. Additional single agent and combination studies are either underway or planned in other solid tumor cancer indications.

LATEST NEWS

Howard J. Federoff, MD, PhD Appointed Chief Executive Officer of Brooklyn ImmunoTherapeutics, Inc.

[ READ MORE ]

Brooklyn ImmunoTherapeutics Completes Reverse Merger with NTN Buzztime

[ READ MORE ]

Brooklyn ImmunoTherapeutics Announces Initiation of Phase 2 Trial of IRX-2 in Combination with Pembrolizumab and Chemotherapy in Triple Negative Breast Cancer

[ READ MORE ]